Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Infections | Internal Medicine | Pulmonology | Journal

Back to Journal Articles

Azithromycin Treats Non-Cystic Fibrosis Bronchiectasis

Last Updated: August 20, 2012.

 

Macrolide antibiotic prevents exacerbations for patients with at least one exacerbation in past year

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with non-cystic fibrosis bronchiectasis with at least one exacerbation in the past year, treatment with the macrolide antibiotic azithromycin correlates with a reduced rate of event-based exacerbations, according to a study published in the Aug. 18 issue of The Lancet, a theme issue on respiratory medicine.

MONDAY, Aug. 20 (HealthDay News) -- For patients with non-cystic fibrosis bronchiectasis with at least one exacerbation in the past year, treatment with the macrolide antibiotic azithromycin correlates with a reduced rate of event-based exacerbations, according to a study published in the Aug. 18 issue of The Lancet, a theme issue on respiratory medicine.

Conroy Wong, M.B., Ch.B., from Middlemore Hospital in Auckland, New Zealand, and colleagues conducted a randomized trial involving patients with non-cystic fibrosis bronchiectasis. Participants, who had had least one pulmonary exacerbation requiring antibiotics in the previous year, were randomized to receive azithromycin (71 patients) or placebo (70 patients) for six months.

The researchers found that, during the six-month treatment period, the rate of event-based exacerbations was significantly lower (0.59 per patient) in the azithromycin group than in the placebo group (1.57 per patient; rate ratio, 0.38). In the azithromycin group there was no change in the prebronchodilator forced expiratory volume in one second, while in the placebo group there was a 0.04 L decrease, but the difference was not significant (P = 0.251). There was no significant difference in the St. George's respiratory questionnaire score between the groups (P = 0.108).

"Azithromycin is a new option for prevention of exacerbations in patients with non-cystic fibrosis bronchiectasis with a history of at least one exacerbation in the past year," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Karate Black Belts Have Differences in Brain Structure Next: Yo-Yo Dieters Still Benefit From Weight Loss Efforts

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.